Fauci Says Johnson & Johnson Vaccine Helpful In Fighting COVID-19 Despite Less Effectiveness

by



[ad_1]

Anthony FauciAnthony Fauci Fauci Says Johnson & Johnson Vaccine Helpful In Fighting COVID-19 Despite Reduced Efficacy Appropriate Use of PCR Needed For Targeted Response To Pandemic Fauci Hopes To See Vaccinations For Children By “ late spring and early summer ” MORE, the government’s leading infectious disease expert, said Johnson & Johnson’s new COVID-19 vaccine is good news in the fight against coronavirus even though it is less effective than other vaccines already in circulation.

“This is actually good news. It’s an added value to the whole effort to bring in more vaccine candidates, ”Fauci told NBC News on Friday evening.

The remarks come after Johnson & Johnson announced that its vaccine is 66% effective in preventing moderate to severe disease, a level of protection higher than the Food and Drug Administration (FDA) minimum but lower than authorized Pfizer and Moderna vaccines. , which are pretty much effective. 95 percent of the time.

The effectiveness of the shot was 72% in the United States but fell to 57% in South Africa, where a new variant of the coronavirus is rife.

“Even though the results showed a 72 percent in the United States, it was a study that involved not only the United States, but also South Africa and Brazil. The important point is that the protection against serious diseases was very high, even in South Africa, where the mutant is dominant, ”said Fauci.

“So even if the numbers compared to mild to moderate illness, 72 percent versus 94-95, clearly 94-95, is better,” he continued. “But from a practical standpoint, of what you want to do to keep people out of the hospital and prevent death, that’s added value.”

Although the effectiveness of the Johnson & Johnson vaccine is lower than that of its competitors, the company pointed out that its vaccine was 85% effective in preventing serious illness and was 100% effective in preventing hospitalization or death in from 28 days after vaccination.

“One of the important things you want to do is keep people out of the hospital. If you can protect them from any kind of symptoms as well, that would be great, ”Fauci said. “Not so good against early disease, but against serious consequences, it is very well done.”

Still, Johnson & Johnson could face what Fauci said could be a “messaging problem” given the title its efficiency lags behind Pfizer and Moderna. And even though it is a single dose vaccine instead of requiring two doses, people may be reluctant to take it.

“There may very well be some people who would actually prefer to have a dose,” Fauci said. “So I think there will be utility, although… some might say, ‘I want the one that is digitally the most efficient.’ It will happen and it will be an email problem. “



[ad_2]

Source link